Eyebright Medical Technology Beijing Co Ltd
Eyebright Medical Technology (Beijing) Co., Ltd. engages in development, production, and commercialization of ophthalmic medical devices in China and internationally. The company offers intraocular, trimmers, capsular tension ring, defocus lense, orthokeratology, and contact lenses in the areas of surgical treatment, myopia management, and consumer vision care. It also provides solutions for opht… Read more
Eyebright Medical Technology Beijing Co Ltd (688050) - Total Assets
Latest total assets as of September 2025: CN¥3.90 Billion CNY
Based on the latest financial reports, Eyebright Medical Technology Beijing Co Ltd (688050) holds total assets worth CN¥3.90 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Eyebright Medical Technology Beijing Co Ltd - Total Assets Trend (2016–2024)
This chart illustrates how Eyebright Medical Technology Beijing Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Eyebright Medical Technology Beijing Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Eyebright Medical Technology Beijing Co Ltd's total assets of CN¥3.90 Billion consist of 33.8% current assets and 66.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 10.4% |
| Accounts Receivable | CN¥358.49 Million | 10.3% |
| Inventory | CN¥272.63 Million | 7.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥309.16 Million | 8.8% |
| Goodwill | CN¥139.11 Million | 4.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Eyebright Medical Technology Beijing Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eyebright Medical Technology Beijing Co Ltd's current assets represent 33.8% of total assets in 2024, a decrease from 36.1% in 2016.
- Cash Position: Cash and equivalents constituted 10.4% of total assets in 2024, down from 18.3% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, a decrease from 21.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 10.3% of total assets.
Eyebright Medical Technology Beijing Co Ltd Competitors by Total Assets
Key competitors of Eyebright Medical Technology Beijing Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Beijing Centergate Technologies Holding Co Ltd
SHE:000931
|
China | CN¥3.82 Billion |
|
Blue Sail Medical Co Ltd
SHE:002382
|
China | CN¥16.46 Billion |
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥28.98 Billion |
|
Allmed Medical Products Co Ltd Class A
SHE:002950
|
China | CN¥5.35 Billion |
|
Inix Technologies Holdings Bhd
KLSE:0094
|
Malaysia | RM72.53 Million |
|
Focus Point Holdings Bhd
KLSE:0157
|
Malaysia | RM328.19 Million |
|
Careplus Group Bhd
KLSE:0163
|
Malaysia | RM286.61 Million |
|
LKL International Bhd
KLSE:0182
|
Malaysia | RM173.46 Million |
Eyebright Medical Technology Beijing Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Eyebright Medical Technology Beijing Co Ltd generates 0.40x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Eyebright Medical Technology Beijing Co Ltd generates $ 11.11 in net profit.
Eyebright Medical Technology Beijing Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.16 | 4.76 | 14.87 |
| Quick Ratio | 3.28 | 3.76 | 14.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.21 Billion | CN¥ 931.25 Million | CN¥ 1.07 Billion |
Eyebright Medical Technology Beijing Co Ltd - Advanced Valuation Insights
This section examines the relationship between Eyebright Medical Technology Beijing Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.89 |
| Latest Market Cap to Assets Ratio | 0.29 |
| Asset Growth Rate (YoY) | 14.2% |
| Total Assets | CN¥3.50 Billion |
| Market Capitalization | $1.03 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Eyebright Medical Technology Beijing Co Ltd's assets below their book value (0.29 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Eyebright Medical Technology Beijing Co Ltd's assets grew by 14.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Eyebright Medical Technology Beijing Co Ltd (2016–2024)
The table below shows the annual total assets of Eyebright Medical Technology Beijing Co Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.50 Billion | +14.21% |
| 2023-12-31 | CN¥3.06 Billion | +36.42% |
| 2022-12-31 | CN¥2.24 Billion | +9.61% |
| 2021-12-31 | CN¥2.05 Billion | +24.97% |
| 2020-12-31 | CN¥1.64 Billion | +138.93% |
| 2019-12-31 | CN¥685.78 Million | +16.94% |
| 2018-12-31 | CN¥586.45 Million | +112.43% |
| 2017-12-31 | CN¥276.06 Million | +18.28% |
| 2016-12-31 | CN¥233.39 Million | -- |